100 Days Mission: 5th Implementation Report and Scorecard

Together with the International Pandemic Preparedness Secretariat, we developed the 100 Days Mission Scorecard to provide a quantifiable state of preparedness for future pandemics.

New data from the 2025 Scorecard shows:

• Limited progress has been made in ecosystem remaining reactive and reliant on US funding.
• R&D funding has declined across most pathogens and product types. Platform technologies remain resilient but are dominated by funding from the US government.
• Therapeutics represent a critical gap due to declining funding and a contracting pipeline. This requires immediate action.
• There is stagnation in the pipeline as most candidates are in Phase 1 with progression limited to early-stage transitions
• Alternative pathways and R&D enablers are underutilised, constraining acceleration opportunities

For the first time, the 100DM Scorecard includes a ‘deep dive’ assessment of pandemic preparedness and response (PPR) capacity in Africa. This new analysis evaluates the continent’s capabilities in clinical trials, laboratory systems, regulatory frameworks and manufacturing, providing a clearer picture of the regional strengths needed to support the 100 Days Mission.

The deep dive assessment shows:

• Clinical trial capacity is geographically clustered, predominantly tethered to single institutions with external, high-income country sponsorship. A decisive shift toward African-led R&D and local principal investigators is needed.
• After the COVID pandemic, regulatory systems were strengthened with additional ML3 designations, yet only two countries currently have the regulatory oversight of local vaccine production. Regional harmonisation initiatives and African Medicines Agency (AMA) operationalisation represent promising advancement.
• Laboratory infrastructure is constrained with only two operational BSL-4 facilities and limited formal inter-laboratory connectivity hampering coordinated research capacity. A coordinated network of BSL-3 and BSL-4 sites is essential for effective regional pathogen detection.
• Manufacturing capability is emerging for vaccine and monoclonal antibody production, though technology transfers and comprehensive capacity data remain critical bottlenecks
• Reaching 100DM objectives is not about every country building end-to-end capacity, but about coordination that leverages the regional 'complement of capacities' to benefit the entire continent.

See pages 26-31 of the report for more information.